AI Article Synopsis
- Genetic translocations commonly occur in cholangiocarcinoma, which initially responds well to FGFR inhibitors.
- Despite the initial effectiveness of these targeted therapies, patients rapidly develop resistance.
- Research by Goyal and colleagues identifies gatekeeper mutations and intratumoral heterogeneity as key factors contributing to this resistance, highlighting important considerations for clinical treatment strategies.
Article Abstract
genetic translocations are frequent in cholangiocarcinoma, yet despite initial sensitivity to FGFR inhibitors in clinic, patients quickly become resistant to targeted therapies. The work published by Goyal and colleagues demonstrates that acquisition of gatekeeper mutations in and intratumoral heterogeneity drive resistance in patients with -translocated intrahepatic cholangiocarcinoma, which will have important implications for management of the disease in clinic. .
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/2159-8290.CD-17-0057 | DOI Listing |
Publication Analysis
Top Keywords
gatekeeper mutations
8
mutations intratumoral
8
intratumoral heterogeneity
8
heterogeneity -translocated
4
-translocated cholangiocarcinoma
4
cholangiocarcinoma genetic
4
genetic translocations
4
translocations frequent
4
frequent cholangiocarcinoma
4
cholangiocarcinoma despite
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!